A/B Only Typed Donors: Possible But Improbable 6/6 HLA Allele Matches  by Dehn, J. et al.
S270 Poster Session IUnivariate analysis of the association between patient/graft charac-
teristics and grade III-IV aGVHD showed the only significant factor
associated with a higher severe aGVHD incidence was age 0-15
years. Multivariate Cox regression analysis was performed (Table).
Younger age was independently associated with a higher severe
aGVHD incidence whereas better engrafting unit-recipient 8-9/10
HLA-allele match was protective. There was a trend toward better
unit-unit HLA-match being associated with worse aGVHD, but,
surprisingly, total infused TNC/kg had no relationship. The 2-
year PFS of 72% (95%CI:51-94) in children was higher than the
56% (95%CI:45-66) in adults despite their greater incidence of se-
vere aGVHD. We conclude that aGVHD after DCBT is common,
predominantly affects the gut, has a high treatment response, chil-
dren are at a higher risk for severe disease, and late GVHD fre-
quently has acute features. While survival is promising, improved
prophylaxis and treatment are needed. A possible approach to reduce
aGVHD in pediatric DCBT recipients with adequate CB unit doses
would be to prioritize high resolution HLA-match. Moreover, our
data does not currently support an upper limit of infused TNC/kg
in DCBT recipients. Further investigation of the biology underlying
these unique observations should be a priority.
Table. Multivariate Analysis
Cumulative
Characteristic Incidence (95% CI) Hazard Ratio P ValueAge (years)
0-15 (n 5 18) 41% (17-65) 2.6 (1.0-6.4) 0.042
$ 16 (n 5 90) 20% (12 -29) Reference -
Engrafting Unit-Recipient 10 Allele HLA-Match
2-7/10 (n 5 83) 27% (17-37) Reference -
8-9/10 (n 5 25) 12% (0-25) 0.3 (0.1-1.0) 0.053
Unit-Unit 10 Allele HLA-Match
0-5/10 (n 5 59) 20% (9-29) Reference -
6-10/10 (n 5 49) 29% (16-42) 2.2 (1.0-5.0) 0.062
Total TNC x107/kg
< 5.0 (n 5 68) 20% (10-29) Reference -
$ 5.0 (n 5 40) 31% (16-46) 1.2 (0.5-2.8) 0.617179
DOUBLE-UNIT CORD BLOOD TRANSPLANTATION (DCBT) FOR ACUTE
LEUKEMIA: HIGH DISEASE-FREE SURVIVAL IN ADULTS AND CHILDREN
WITH COMPARABLE SURVIVAL IN EUROPEAN AND MINORITY PATIENTS
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As DCBT may improve engraftment and protect against relapse,
we have adopted DCBT for children and adults with high-risk acute
leukemia, myelodysplasia (MDS), and myeloproliferative diseases
(MPD). We analyzed DFS in 75 DCBT recipients with acute leuke-
mia in morphologic remission or aplasia (n 5 69), and MDS/MPD
with # 5% blasts (n 5 6) transplanted 10/2005-4/2011. Children
(n5 23, 43% AML, 52% ALL, and 4%MDS/MPD) were a median
of 9 years (range 0.9-15) and 37 kg (range 7-72), 30% were
European, and 26% were CMV sero-positive. All received high-
dose conditioning. Pediatric grafts had a median infused TNC x
107/kg of 3.3 (larger unit) and 2.6 (smaller unit), and 2% of units
were 6/6 HLA-A,-B antigen,-DRB1 allele matched, 63% 5/6, and
35% 4/6. Adults (n 5 52, 63% AML, 27% ALL, and 10% MDS/
MPD) were a median of 41 years (range 16-69) and 69 kg (range
47-105), 48% were European, and 69% were CMV sero-positive.
Fifty percent received high-dose and 50% reduced intensity condi-
tioning. Their units had median infused TNC/kg of 2.7 and 1.9,
and 3%were 6/6HLA-matched, 47% 5/6, and 50% 4/6. All patients
received calcineurin-inhibitor/ mycophenolate mofetil immunosup-
pression. Sustained neutrophil engraftment was seen in 91% of chil-
dren and 94% of adults at medians of 20 and 26 days, respectively.
Day 180 grade II-IV acute GVHD incidence was 44% in childrenand 58% in adults. Day 100 transplant-related mortality was 9% in
children and 19% in adults. 2-year relapse incidence was 9% in chil-
dren and 6% in adults. With a median survivor follow-up of 26
months (range 4-70), 2-year DFS was 78% in children and 64% in
adults. Univariate analysis of variables potentially influencing 2-
year DFS is shown (Table). There were no differences in 2-year
DFS according to ancestry, remission status, conditioning intensity,
engrafting unit infused TNC dose/kg, or engrafting unit-recipient
HLA-match (4-6/6 or 10 allele). However, CMV seronegative pa-
tients had a higher 2-year DFS (85% vs 55%, p 5 0.018). Multivar-
iate analysis revealed CMV serostatus was a DFS predictor
independent of patient age. We have previously shown that DCBT
extends transplant access to minorities. We now demonstrate that
DCBT can achieve high and comparable DFS in European and
non-European pediatric and adult leukemia patients. Our findings
support DCBT as an immediate alternative for high-risk acute leu-
kemia patients without rapidly available unrelated donors, especially
given the very low relapse incidence.
Table.
Comparison 2-Year DFS P ValueAncestry Europeans (n 5 32) 67% 0.884
Non-Europeans (n 5 43) 69%Remission CR1 (n 5 41) 69% 0.663
Status All others (n 5 34) 67%
Conditioning High-dose (n 5 49) 71% 0.687
Intensity Reduced intensity (n 5 26) 62%
Recipient CMV CMV+ (n 5 42) 55% 0.018
Sero-status CMV- (n 5 33) 85%
Engrafting Unit < 3.0 x 107/kg (n 5 56) 65% 0.307
Infused TNC Dose $ 3.0 x 107/kg (n 5 19) 77%
Engrafting Unit-recipient 4/6 (n 5 30) 72% 0.596
Match (4-6/6) 5-6/6 (n 5 45) 65%
Engrafting Unit-recipient 2-6/10 (n 5 41) 64% 0.418
Match (10 allele) 7-9/10 (n 5 34) 73%180
A/B ONLY TYPED DONORS: POSSIBLE BUT IMPROBABLE 6/6 HLA ALLELE
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Background: Patients searching the Be The Match Registry are
evaluated for HLA matching with over 9.5 million donors, 88% with
a minimum of HLA-A/B/DRB1 typing and 12% with HLA-A/B
only (i.e., noDRB1) typing. Patients with no potential 6/6 HLA allele
matched donors present a challenging search for which transplant
centers may consider DRB1 typing of A/B only donors. Selection of
A/B only donor typing varies by center, so a study was performed to
evaluate the utility of this practice in identifying A/B/DRB1 (6/6)
matched donors given the size of the Be The Match Registry.
Methods:We identified 180 new patient searches with no potential
6/6 HLA allele matched donors, reviewed the search results, and
typed DRB1 on a total of 2,976 A/B only donors with stored DNA
samples. The median number of tested A/B only donors per patient
was 4, ranging from 1 to 231. Donor DRB1 typing results were com-
pared to the corresponding patient’s DRB1 alleles to confirm high
resolution match status.
Results: Of 2,976 donors typed for 180 patients, two donors
matched their respective patient’s DRB1 typing. One DRB1
matched donor became a 10/10 match to the patient whose search
previously contained no 6/6 potential matches. This donor carried
an A/B/DRB1 phenotype that had not previously been identified his-
torically in a Be The Match Registry donor.
Conclusions: These results show very limited benefit to HLA-A/B
only donor testing for the patients considered in this study, with only
two patients identifying a DRB1 matched donor. With most A/B
only donors typed by serology, additional mismatches are possible.
Since only donors with stored DNA samples were tested (26% of
the total A/B only donors), additional DRB1 matches may have
been identified if every A/B only donor for each patient were tested.
Study patients represented challenging searches with no potential
Poster Session I S2716/6 matched A/B/DRB1 typed donors. The strategy of selecting A/B
only typed donors may pose a different success rate given the sce-
nario of a patient search with one or more existing A/B/DRB1
matched donors, as this implies a more frequent HLA phenotype.
While the probability of finding a 6/6 allele matched donor from
the A/B only pool is likely very low, the possibility does exist, even
when a patient’s A/B/DRB1 phenotype is uncommon. With the
low incidence of success, the strategy of pursuing A/B only typed do-
nor testing may be best accomplished in conjunction with selection
of the best mismatched potential donor.
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AN EVALUATION OF PERIPHERAL BLOOD STEM CELL DONATIONS BY
ADULT DONORS $ 60 YEARS OF AGE
Jakubowski, A.A., Maloy, M., Petrlik, E., Boulad, F., Castro-
Malaspina, H., Koehne, G., Papadopoulos, E.B., Perales, M.-A.,
Young, J.W., Giralt, S. Memorial Sloan Kettering Cancer Center, New
York, NY
Introduction:With the increasing age of the stem cell transplant re-
cipient, the age of related donors (RD) has also increased. To deter-
mine the stem cell yield and adequacy of collection for donors $ 60
yrs, we performed a single center retrospective review.
Methods:The dose of CD34+ cells/kg patient weight in grafts from
RDs age$ 60 yrs was reviewed from January 2001-March 2011. The
grafts included only donations of G-CSFmobilized peripheral blood
stem cells (PBSC) a proportion of which were T cell depleted
(TCD). TCD was accomplished by CD34+ selection using an auto-
mated system and resulted in only a small loss of stem cells. These
results are compared to an equal number of grafts obtained from
RDs\60 yrs during the same period.
Results: A total of 59 RDs $ 60 yrs were identified, median age 63
(range 60-76) yrs. Twenty five RDs were used for conventional
grafts, and 34 for TCD grafts without any serious complications.
The median dose of CD34+cells/kg from each was 7.2 (range 2.25-
21.1) and 8.36 (range 1.74-28.8) x 106/kg, respectively. All pts who
received these grafts achieved engraftment. During the same period
of time, 70 RDs\60 yrs (range 20-50 yrs) provided similar conven-
tional and TCD grafts for the comparison group. For 27 younger
RDs who provided conventional grafts and 43 TCD grafts, the me-
dian CD34+/kg cell doses were 8.5 (range 2-26.3) and 8 (range 1.39-
28.4.8) x 106, respectively.
Conclusions: Adults.60 yrs are the fastest growing segment of the
US population. Estimates suggest that in 30 yrs, that group will
nearly double, increasing it to approx. 20% of the population. These
data support consideration of individuals $ 60 yrs as stem cell do-
nors. Further study is needed to demonstrate that donor age does
not impact on transplant outcome.
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EPSTEIN-BARR VIRUS-RELATED COMPLICATIONS (EBV-RC) AFTER
UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) FOR ADULT
PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES
Sanz, J., Jaramillo, F., Montesinos, P., Martinez-Cuadron, D.,
Lorenzo, I., Palau, J., Martin, G., Jarque, I., De La Rubia, J.,
Moscardo, F., Martinez, J., Sanz, M., Sanz, G. Hospital Universitario
La Fe, Valencia, Spain
Incidence and characteristics of EBV-RC after UCBT are not well
established, although an increased risk of EBV-RC has been sug-
gested with the addition of antithymocyte globulin (ATG) to a non-
myeloablative conditioning. This study tries to identify incidence
and relevant risk factors for the development of EBV-RC in adults
with hematologic malignancies undergoing UCBT at a single
institution.
Two hundred and thirty consecutive patients (143 males, 87 fe-
males) with median age of 34 years (range, 15-59) who underwent
single-unit UD-UCBT at Hospital Universitario La Fe from Janu-
ary 1997 until April 2011 were included in the analysis.Seventy five
(32%) had acute myeloid leukemia, 75 (32%) acute lymphoblastic
leukemia, 28 (13%) chronic myeloid leukemia, 19 (9%)myelodispla-
sic syndrome, 12 (5%) non-Hodgkin lymphoma, 8 (4%) Hodgkin
lymphoma while the remaining 13 patients (5%) had a variety of he-
matological diseases. All patients received conditioning consisted of
thiotepa, busulfan, cyclophosphamide or fludarabine, and ATG.Two-hundred and seven patients received myeloablative condition-
ing regimen (MAC) while the remaining 23 received RIC with the
same schedule but using a reduced dose of thiotepa (5 mg/kg) and
IV busulfan (6.4 mg/kg). Cyclosporine and prednisone or cyclospor-
ine and mycophenolate mofetil were used for graft-versus-host
disease prophylaxis. Most patients (96%) received an HLA-mis-
matched single UCB unit with 1 (24%), 2 (71%) or 3 (1%)
mismatches with the recipient. At cryopreservation, the median
number of total nucleated cells (TNC) was 3 x107/kg (range, 1.4-
8.5) and median number of CD34+ cells was 1.6 x105/kg (range,
0.2-6.8). Eleven patients developed EBV-RC at a median of 67
days (range 36-258). Two patients presenting with EBV viremia re-
ceived pre-emptive therapy with Rituximab, while the remaining 9
patients died of EBV posttransplantation lymphoproliferative disor-
der. The overall cumulative incidence (CI) of EBV-RCwas 4,8% at 2
years. The CI of EBV-RC was significantly higher in the subset of
patients treated with RIC (26% vs 2%; p\ 0.01) and patients with
a diagnosis of Hodgkin lymphoma (50% vs 3%; p\0.01). These re-
sults confirm that EBV-RC are relatively rare in adults undergoing
UCBT after ATG-containing MAC, however the risk is markedly
increased in RIC recipients. Interestingly, a significant risk of
EBV-RC for patients with Hodgkin lymphoma undergoing UCBT
was also observed.183
HIGHLY SIGNIFICANT IMPACT OF HLA-DRB3 AND -DRB4 MATCHING ON
DIFFERENT UNRELATED ALLO-HSCT OUTCOMES: NEW PERSPECTIVES
IN THE UNRELATED DONOR SELECTION
Detrait, M.1, Dubois, V.2, Sobh, M.1, Morisset, S.1, Nicolini, F.E.1,
Labussiere, H.1, Barraco, F.1, Ducastelle, S.1, Thomas, X.1,
Tedone, N.1, Chelghoum, Y.1, Rey, S.2, Michallet, M.1 1Centre Hospital-
ier Lyon Sud, Pierre Benite, France; 2Etablissement Franc¸ais du Sang,
Lyon, France
We examined retrospectively in our center the outcome of 30 pa-
tients who received unrelated HSCT with a HLA-DRB3 or -DRB4
mismatched donor (study group) and we compared with a cohort of
30 patients (control group) with the same characteristics except for
the DRB3 or DRB4 donor mismatching. In the study group, there
were 16 patients with 10/10 HLA identical donor among them 11
had a DRB3 mismatch and 5 had a DRB4 mismatch. There were
14 patients with 9/10 HLA identical donor among them 9 had
a DRB3 mismatch and 5 had a DRB4 mismatch. In the control
group, there were 16 patients with 10/10 HLA identical donor and
14 patients with 9/10 HLA identical donor. After HSCT, 27
(90%) patients in the study group engrafted while 29 (96%) en-
grafted in the control group. The cumulative incidence of acute
GVHD$2 at 3 months was 37% (95%CI, 28-46) and 30% (95%
CI, 22-39) for the study and control groups respectively, with
a same cumulative incidence of chronic GVHD at one year of
20% (95%CI, 12-28). At day 90 post HSCT, 17 (63%) patients in
the study groupwere in CR and 25 (86%) inCR in the control group.
After a median follow-up of 5 months (range, 0.2-46) and 13 months
(range, 0.5-60) for study and control groups respectively, the median
OS was 7 months (range, 3-32) and 21 months (range, 11-NR) with
a 2-years probability of 25% (95%CI, 12-51) and 41% (95%CI, 25-
69) respectively; the median PFS was 3 months (range, 0.2-46) and
10 months (range, 1-60) with a 2-years probability of 16% (95%
CI, 6-42) and 37% (95%CI, 21-63) respectively. The cumulative in-
cidence of relapse at 1 year was the same for the two groups with 30%
(95%CI, 22-39); the cumulative incidence ofTRMat 3months and 1
year were 17% (95%CI, 10-24) vs. 3% (95%CI, 0-7) and 37% (95%
CI, 28-46) vs. 10% (95%CI, 5-16) for study and control groups re-
spectively. The multivariate analysis showed a significant worse OS
in 9/10 mismatched patients with or without a DRB3 or DRB4
mismatch (HR 5 5.3; [95%CI, 1.6-18] p 5 0.006); 10/10 matched
patients with a DRB3 or DRB4 mismatch (HR 5 3.9; [95%CI,
1.2-12] p 5 0.02) and patients not in CR at transplantation (HR 5
4.4; [95%CI, 1.6-12] p 5 0.004); similarly, the same groups had
a worse TRM in multivariate analysis, (HR 5 6; [95%CI, 1.5-24]
p 5 0.02) and (HR 5 3.5; [95%CI, 1.02-12] p 5 0.04) respectively.
In view of the important impact of these loci mismatches on clinical
outcome, it should be considered in the unrelated donor selection.
